Total
0
Shares
Patrys (ASX:PAB) lands Australian patent for cancer treatment platform
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cancer treatment company Patrys (PAB) has landed an Australian patent for its Deoxymab 3E10 nanoparticle technology
  • The company's flagship treatments, such as its PAT-DX1-NP, fall under the umbrella of the Deoxymab platform, meaning they are covered by the patent
  • Patrys' cancer treatment is designed to bind to DNA outside of the cells and then follow the DNA into the cancer cells
  • From there, it stops the cancer cells from repairing themselves, and they eventually die
  • This type of treatment can preferentially target cancer cells and bypass the important blood-brain barrier (BBB)
  • On top of today's Australian patent, the treatment is patented in Europe, China, Japan, and the United States
  • Shares in Patrys gained 20 per cent today to close worth 1.8 cents each

Patrys (PAB) has landed an Australian patent for its Deoxymab 3E10 nanoparticle technology.

The company's flagship treatments, such as its PAT-DX1-NP, fall under the umbrella of the Deoxymab platform, meaning they are covered by the patent.

Essentially, this type of cancer treatment is designed to bind to DNA outside of cells, then follow the DNA into cancer cells and disrupt the natural DNA repair process.

The result is that Patrys' treatments, like PAT-DX1, preferentially target tumours and cancer cells and stop the cells from repairing themselves so they eventually die.

Patrys touts the Deoxymab platform as one of the world's first cell-penetrating anti-DNA antibodies for the treatment of cancer.

Company CEO and Managing Director Dr James Campbell said PAT-DX1 can target a range of specific cancers, regardless of their type.

"Our PAT-DX1 antibody is unique in that it binds to the DNA that is released from many solid cancers which results from the high turnover of cells in solid tumours," James said.

"We have combined this broad-spectrum, tumour-targeting approach with nanoparticles that are able to carry a payload anti-cancer drugs that are toxic to the cancer. This combination allows us to specifically deliver cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells in the body," he explained.

Importantly, the drug is able to bypass the blood-brain barrier (BBB), which is a barrier protecting our central nervous system (CNS) from potential infection. This means PAT-DX1 has the potential to treat brain cancers and other CNS cancers that have spread from a different part of the body.

Now, this treatment is patented in Australia.

On top of the Australian patent, Patrys has five patents covering the unconjugated form of PAT-DX1 in different parts of the world: one in Europe, Japan, and China, and two in the United States.

Moreover, the company has 19 patent applications pending across 10 different patent families.

Following today's news, shares in Patrys soared 20 per cent to close worth 1.8 cents each. The company has a $25.74 million market cap.

PAB by the numbers
More From The Market Herald
Jayex Healthcare (ASX:JHL) - Executive Chairman, Michael Boyd - The Market Herald

" Jayex Healthcare’s (ASX:JHL) NZ subsidiary secures cultivation licence

Jayex Healthcare’s (JHL) wholly-owned subsidiary, Whakaora Hou, has successfully obtained a cultivation licence for medical marijuana.
TALi Digital (ASX:TD1) - Managing Director, Glenn Smith - The Market Herald

" TALi Digital (ASX:TD1) partnership goes live

TALi Digital’s (TD1) partnership with Times Group of India has gone live to the Indian consumer market ahead of schedule.
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) receives CE Mark approval for COVID-19 test

AnteoTech (ADO) has received Conformitè Europëenne (CE) Mark registration for its rapid test platform and COVID-19 test.
Imugene (ASX:IMU) - CEO, Leslie Chong - The Market Herald

" Imugene (ASX:IMU) presents key findings to leading cancer research association

Imugene (IMU) presented key findings from its HER-Vaxx immunotherapy and CF33 oncolytic virus programs at the American Association for Cancer Research’s annual meeting.